Barclays raised the firm’s price target on Alnylam (ALNY) to $527 from $460 and keeps an Overweight rating on the shares. The company reported another “strong beat and raise” quarter, but the stock traded down on narrowly missing buyside expectations, less robust guidance and a subpoena, the analyst tells investors in a research note. The firm’s analysis of subpoena cases suggests “limited concern.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $475 from $400 at Chardan
- Alnylam Pharmaceuticals Reports Strong Q3 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Alnylam Pharma’s Strong Q3 Performance and Promising Outlook Reinforce Buy Rating Despite Legal Concerns
- Alnylam price target raised to $495 from $475 at Morgan Stanley